• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Drug Dev Ind Pharm . Reckoning γ-Glutamyl-S-allylcysteine as a potential Main protease (M pro) inhibitor of novel SARS-CoV-2 virus identified using

tetano

Editor, Senior Moderator
Drug Dev Ind Pharm


. 2021 May 26;1-32.
doi: 10.1080/03639045.2021.1934857. Online ahead of print.
Reckoning γ-Glutamyl-S-allylcysteine as a potential Main protease (M [SUP]pro[/SUP]) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation


Arun Parashar[SUP] 1 [/SUP], Arpit Shukla[SUP] 2 3 [/SUP], Ankush Sharma[SUP] 4 [/SUP], Tapan Behl[SUP] 5 [/SUP], Dweipayan Goswami[SUP] 3 [/SUP], Vineet Mehta[SUP] 6 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 or COVID-19), outbreak was first reported in December 2019 in the Wuhan, China. COVID-19 managed to spread worldwide and so far more than 9.1 million cases and more than 4.7 lakh death has been reported globally. Children, pregnant women, elderly population, immunocompromised patients, and patients with conditions like asthma, diabetes, etc. are highly vulnerable to COVID infection. Currently, there is no treatment available for COVID-19 infection. Traditional medicinal plants have provided bioactive molecules in the past that are efficiently used during conditions like cancer, malaria, microbial infections, immune-compromised states, etc. AYUSH India has recommended the use of Curcuma longa, Allium sativum, Ocimum tenuiflorum, and Withania somnifera for immune-boosting during SARS-CoV-2 infection. In the present study, we investigated the potential of 63-major bioactive molecules of these plants against SARS-CoV-2 main protease (M[SUP]pro[/SUP]) through docking studies and compared the results with known inhibitor 11a. Our results proposed cuscohygrine, γ-Glutamyl-S-allylcysteine, anahygrine, and S-allylcystein as the potent inhibitors against M[SUP]pro[/SUP] identified using molecular docking and molecular simulation dynamics. Interestingly, these molecules are from A. sativum, and W. somnifera, which are known for their antimicrobial and immunomodulatory potential. None of the proposed molecules have earlier been reported as antiviral molecules. Our results predict very strong potential of these four-molecules against SARS-CoV-2 M[SUP]pro[/SUP], especially γ-glutamyl-S-allylcysteine, as all four form hydrogen bonding with Glu166 that is a crucial residue for the formation of the biologically active dimeric form of M[SUP]pro[/SUP]. Therefore, we strongly recommend further research on these biomolecules against SARS-CoV-2.

Keywords: Allium sativum; COVID-19; Coronavirus; Molecular Docking; SARS-CoV-2; Withania somnifera.
 
Back
Top Bottom